PST 2238 as an antihypertensive compound that antagonizes the effect of endogenous cardiac glycosides.
This review examines the role of endogenous cardiac glycosides (OLF--ouabain like factors) in the pathogenesis of hypertension. The discovery of ouabain as a new adrenal hormone affecting salt and water homeostasis has initiated research on a new group of compounds. OLF may provide new insights into the mechanisms and therapy of common cardiovascular diseases. PST 2238 (17beta-(3-furyl)-5beta-androstane-3beta-14beta-17alpha-triol), an antagonist of endogenous ouabain, might open new possibilities for the therapy of hypertension and congestive heart failure.